Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Lancaster

Showing results (41-50 of 74) with videos related to

Pageof 8
Sort By:
Chest|July 2, 2009
Obstructive sleep apnea is common in idiopathic pulmonary fibrosisLisa H Lancaster, Wendi R Mason, James A Parnell, et al.
ATS Scholar|October 1, 2025
Pulmonary Hypertension Associated with Interstitial Lung Disease: Screening and EpidemiologyCedric Rutland, Chase S Hall, Nicholas A Kolaitis, et al.
Chest|July 29, 1999
Use of genetically altered mice to investigate the role of nuclear factor-kappa B activation and cytokine gene expression in sepsis-induced ARDST S Blackwell, F E Yull, C L Chen, et al.
American Journal of Respiratory and Critical Care Medicine|September 16, 2000
Multiorgan nuclear factor kappa B activation in a transgenic mouse model of systemic inflammationT S Blackwell, F E Yull, C L Chen, et al.
BMJ Open Respiratory Research|August 18, 2018
Dose modification and dose intensity during treatment with pirfenidone: analysis of pooled data from three multinational phase III trialsSteven D Nathan, Lisa H Lancaster, Carlo Albera, et al.
American Journal of Respiratory and Critical Care Medicine|August 29, 2022
Peripheral Blood Telomere Attrition in Persons at Risk for Familial Pulmonary FibrosisMargaret L Salisbury, Cheryl R Markin, Pingsheng Wu, et al.
European Respiratory Review : an Official Journal of the European Respiratory Society|December 8, 2017
Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosisLisa H Lancaster, Joao A de Andrade, Joseph D Zibrak, et al.
American Journal of Respiratory and Critical Care Medicine|August 9, 2017
A Phase 2 Randomized Controlled Study of Tralokinumab in Subjects with Idiopathic Pulmonary FibrosisJoseph M Parker, Ian N Glaspole, Lisa H Lancaster, et al.
Chest|November 26, 2018
Efficacy of Pirfenidone in the Context of Multiple Disease Progression Events in Patients With Idiopathic Pulmonary FibrosisSteven D Nathan, Ulrich Costabel, Ian Glaspole, et al.
Annals of the American Thoracic Society|April 6, 2019
Pirfenidone Treatment in Individuals with Idiopathic Pulmonary Fibrosis: Impact of Timing of Treatment InitiationToby M Maher, Lisa H Lancaster, Stéphane Jouneau, et al.
Pageof 8

Showing results (41-50 of 74) with videos related to

Sort By:
Pageof 8
Chest|July 2, 2009
Obstructive sleep apnea is common in idiopathic pulmonary fibrosisLisa H Lancaster, Wendi R Mason, James A Parnell, et al.
ATS Scholar|October 1, 2025
Pulmonary Hypertension Associated with Interstitial Lung Disease: Screening and EpidemiologyCedric Rutland, Chase S Hall, Nicholas A Kolaitis, et al.
Chest|July 29, 1999
Use of genetically altered mice to investigate the role of nuclear factor-kappa B activation and cytokine gene expression in sepsis-induced ARDST S Blackwell, F E Yull, C L Chen, et al.
American Journal of Respiratory and Critical Care Medicine|September 16, 2000
Multiorgan nuclear factor kappa B activation in a transgenic mouse model of systemic inflammationT S Blackwell, F E Yull, C L Chen, et al.
BMJ Open Respiratory Research|August 18, 2018
Dose modification and dose intensity during treatment with pirfenidone: analysis of pooled data from three multinational phase III trialsSteven D Nathan, Lisa H Lancaster, Carlo Albera, et al.
American Journal of Respiratory and Critical Care Medicine|August 29, 2022
Peripheral Blood Telomere Attrition in Persons at Risk for Familial Pulmonary FibrosisMargaret L Salisbury, Cheryl R Markin, Pingsheng Wu, et al.
European Respiratory Review : an Official Journal of the European Respiratory Society|December 8, 2017
Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosisLisa H Lancaster, Joao A de Andrade, Joseph D Zibrak, et al.
American Journal of Respiratory and Critical Care Medicine|August 9, 2017
A Phase 2 Randomized Controlled Study of Tralokinumab in Subjects with Idiopathic Pulmonary FibrosisJoseph M Parker, Ian N Glaspole, Lisa H Lancaster, et al.
Chest|November 26, 2018
Efficacy of Pirfenidone in the Context of Multiple Disease Progression Events in Patients With Idiopathic Pulmonary FibrosisSteven D Nathan, Ulrich Costabel, Ian Glaspole, et al.
Annals of the American Thoracic Society|April 6, 2019
Pirfenidone Treatment in Individuals with Idiopathic Pulmonary Fibrosis: Impact of Timing of Treatment InitiationToby M Maher, Lisa H Lancaster, Stéphane Jouneau, et al.
Pageof 8